Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral tebipenem vs IV imipenem-cilastatin in cUTI/AP
2023-503785-22-00Phase 3Completed
- Sponsor
- Spero Therapeutics
- Start
- Feb 2024
- Modality
- Drug Delivery Systems
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Spero Therapeutics. Primary endpoint: Overall response at TOC in micro-ITT. Started Feb 2024; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2023-503785-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503785-22-00.